Exelixis

This early-stage trial tests a new drug, XB371, in about 150 people whose solid tumors have spread or come back. The main goal is to check the drug's safety and find the right dose. Participants must be in fairly good health and have a life expectancy of at least 12 weeks.

This early-stage study tests a new drug called XL092, alone or with other immune-boosting drugs, in people with advanced solid tumors (like kidney, prostate, lung, or colon cancer) that can't be removed by surgery. The main goals are to find safe doses and see if the treatment sh…

This early-stage study tests a new drug called XB010, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. About 396 adults with cancers…

This study tests a new drug called XL309, alone or with another drug (olaparib), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 429 adults w…

This study tests a new drug called zanzalintinib against the current standard drug everolimus in people with advanced neuroendocrine tumors that have already been treated. About 440 adults with tumors that cannot be removed by surgery or have spread will be randomly assigned to o…

This early-phase trial tests a new drug called XB628 in about 75 people whose advanced solid tumors have not responded to standard treatments. XB628 is designed to help the body's natural killer cells attack cancer cells more effectively. The main goals are to check safety and fi…